229 completed. 229 Phase 3, 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 229 | Completed 229 |
| Phase 2 | 7 | Completed 7 |
Follow Hypercholesterolemia: new trials by email Literature Review of Hypercholesterolemia trials Research Report on Hypercholesterolemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of AG2304T and AG2304R AG2304T, AG2304R - Hypercholesterolemia | Phase 3 | Completed | Ahn-Gook Pharmaceuticals Co.,Ltd | 158 | 2024-09-30 | 2026-06-18 |
| A Study to Evaluate the Efficacy and Safety of Enlicitide (MK-0616, Oral PCSK9 Inhibitor) Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With Hypercholesterolemia (MK-0616-018/CORALreef AddOn) Enlicitide, Ezetimibe, Bempedoic Acid - Hypercholesterolemia | Phase 3 | Completed | Merck Sharp & Dohme LLC | 301 | 2024-07-08 | 2026-03-27 |
| Study of Obicetrapib & Ezetimibe Fixed Dose Combination on Top of Maximum Tolerated Lipid-Modifying Therapies Combination Therapy, Monotherapy obicetrapib, Monotherapy ezetimibe - Dyslipidemias, Hypercholesterolemia | Phase 3 | Completed | NewAmsterdam Pharma | 407 | 2024-03-01 | 2025-10-08 |
| A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Safety and Efficacy of SAL003 in Combination With Statin Therapy in Patients With Hypercholesterolemia and Mixed Dyslipidemia SAL003 140 mg, Placebo - Hyperlipidemias, Hypercholesterolemia, Mixed Dyslipidemia | Phase 3 | Completed | Shenzhen Salubris Pharmaceuticals Co., Ltd. | 720 | 2023-12-19 | 2025-11-28 |
| A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-013) CORALreef Lipids Enlicitide Decanoate, Placebo - Hypercholesterolemia, Familial Hypercholesterolemia | Phase 3 | Completed | Merck Sharp & Dohme LLC | 2912 | 2023-08-10 | 2026-09-24 |
| A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Heterozygous Familial Hypercholesterolemia (MK-0616-017/CORALreef HeFH) Enlicitide Decanoate, Placebo - Hypercholesterolemia, Familial Hypercholesterolemia | Phase 3 | Completed | Merck Sharp & Dohme LLC | 303 | 2023-08-08 | 2026-02-24 |
| Efficacy and Safety of Inclisiran as Monotherapy in Chinese Adults With Low or Moderate ASCVD Risk and Elevated Low-density Lipoprotein Cholesterol. Inclisiran, Matching Placebo for Inclisiran - Primary Hypercholesterolemia or Mixed Dyslipidemia | Phase 3 | Completed | Novartis Pharmaceuticals | 207 | 2023-07-11 | 2026-01-13 |
| A Phase III Confirmatory Study of K-877 (Pemafibrate) in Patients With Hypercholesterolemia and Statin Intolerance K-877 0.2 mg/day (once daily), K-877 0.4 mg/day (once daily), Placebo (once daily) - Hypercholesterolemia | Phase 3 | Completed | Kowa Company, Ltd. | 71 | 2023-05-01 | 2025-12-11 |
| Efficacy and Safety of Inclisiran as Monotherapy in Patients With Primary Hypercholesterolemia Not Receiving Lipid-lowering Therapy. Inclisiran, Ezetimibe, Matching Placebo for Inclisiran - Hypercholesterolemia | Phase 3 | Completed | Novartis Pharmaceuticals | 350 | 2023-03-15 | 2025-10-16 |
| Clinical Trial to Evaluate the Efficacy and Safety of DW1125 and DW1125A Ezetimibe/Atorvastatin 10/5 mg, Atorvastatin 5mg, Ezetimibe 10mg - Hypercholesterolemia, Dyslipidemia | Phase 3 | Completed | Daewon Pharmaceutical Co., Ltd. | 252 | 2022-08-17 | 2023-08-01 |
| Efficacy and Safety of Ezetimibe/Rosuvastatin and Amlodipine Patients With High Blood Pressure and High Cholesterol Amlodipine, Ezetimibe/Rosuvastatin, Ezetimibe/Rosuvastatin Placebo - Hypertension, Hypercholesterolemia | Phase 3 | Completed | Celltrion Pharm, Inc. | 163 | 2022-08-05 | 2026-05-08 |
| Evaluate the Effect of Obicetrapib in Patients With HeFH on Top of Maximum Tolerated Lipid-Modifying Therapies. Obicetrapib, Placebo - Dyslipidemias, High Cholesterol | Phase 3 | Completed | NewAmsterdam Pharma | 354 | 2022-07-25 | 2025-06-11 |
| Trial to Evaluate Efficacy and Safety of LIB003 and Inclisiran in High-risk CVD Patients lerodalcibep, Inclisiran - Hypercholesterolemia, Atherosclerotic Ischemic Disease | Phase 3 | Completed | LIB Therapeutics LLC | 166 | 2022-06-20 | 2024-10-23 |
| Improved Diagnosis of Familial Hypercholesterolemia Across the Northland (ID-FH) Motivational interview (MI) - Familial Hypercholesterolemia, Cholesterol, Elevated | Phase 3 | Completed | Essentia Health | 257 | 2022-02-15 | 2026-09-04 |
| Cross-Over Study to Compare the Pharmacokinetics and Pharmacodynamics of LIB003 Process 1 and Process 2 Drug Product lerodalcibep - Hypercholesterolemia | Phase 3 | Completed | LIB Therapeutics LLC | 22 | 2022-01-28 | 2022-07-14 |
| Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies Placebo, Obicetrapib - Dyslipidemias, High Cholesterol | Phase 3 | Completed | NewAmsterdam Pharma | 2530 | 2021-12-15 | 2025-09-19 |
| Technology-Assisted Cholesterol Trial in Consumers (TACTiC) 5 mg rosuvastatin calcium with a Web App (combination product) - High Cholesterol | Phase 3 | Completed | AstraZeneca | 1196 | 2021-07-08 | 2024-10-30 |
| A Randomized Study to Evaluate the Effect of an "Inclisiran First" Implementation Strategy Compared to Usual Care in Patients With Atherosclerotic Cardiovascular Disease and Elevated LDL-C Despite Receiving Maximally Tolerated Statin Therapy (VICTORION-INITIATE) Inclisiran - Atherosclerotic Cardiovascular Disease | Phase 3 | Completed | Novartis Pharmaceuticals | 450 | 2021-06-25 | 2025-05-16 |
| Management of LDL-cholesterol With Inclisiran + Usual Care Compared to Usual Care Alone in Participants With a Recent Acute Coronary Syndrome Inclisiran - Acute Coronary Syndrome | Phase 3 | Completed | Novartis Pharmaceuticals | 400 | 2021-06-24 | 2025-10-16 |
| Trial to Evaluate Efficacy and Safety of LIB003, Evolocumab and Alirocumab in High-risk CVD Patients lerodalcibep, evolocumab, alirocumab - Hypercholesterolemia, Cardiovascular Diseases | Phase 3 | Completed | LIB Therapeutics LLC | 204 | 2021-04-22 | 2023-03-29 |
Showing 20 of 229. Sign in to see all of them.
Hyperlipidemias (37) · Dyslipidemias (35) · Hyperlipoproteinemia Type II (22) · Atherosclerosis (21) · Coronary Disease (20) · Hypertension (15) · Cardiovascular Diseases (12) · Diabetes Mellitus (10) · Homozygous Familial Hypercholesterolemia (8) · Diabetes Mellitus, Type 2 (6) · Heart Diseases (5) · Hypertriglyceridemia (5) · Metabolic Diseases (5) · Stroke (5)
Nutritional and Metabolic Diseases (229) · Lipid Metabolism Disorders (225) · Metabolic Diseases (224) · Dyslipidemias (194) · Hyperlipidemias (192) · Vascular Diseases (50) · Cardiovascular Diseases (44) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (24) · Arterial Occlusive Diseases (22) · Metabolism, Inborn Errors (22) · Arteriosclerosis (21) · Heart Diseases (21) · Hyperlipoproteinemias (21) · Lipid Metabolism, Inborn Errors (21) · Myocardial Ischemia (21)
Ezetimibe (75) · Atorvastatin (54) · Rosuvastatin Calcium (42) · Simvastatin (40) · evolocumab (25) · alirocumab (22) · Ezetimibe, Simvastatin Drug Combination (10) · 1-((1-(3-acetoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl)acetyl)piperidine-4-acetic acid (8) · pitavastatin (8) · 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid (7) · Pravastatin (7) · ALN-PCS (6) · Duration of Therapy (6) · mipomersen (6) · Amlodipine (5)
Organon and Co (55) · Amgen (23) · AstraZeneca (22) · Sanofi (18) · Merck Sharp & Dohme LLC (9) · Takeda (8) · Kowa Research Europe (7) · Esperion Therapeutics, Inc. (6) · Kastle Therapeutics, LLC (5) · National Heart, Lung, and Blood Institute (NHLBI) (5) · Novartis Pharmaceuticals (5) · Novartis (4) · Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (4) · Regeneron Pharmaceuticals (4) · Kowa Company, Ltd. (3)
United States (83) · Canada (49) · Netherlands (40) · Spain (38) · United Kingdom (38) · Germany (34) · South Africa (33) · Czechia (30) · Denmark (27) · France (27) · Italy (27) · Belgium (24) · Norway (23) · Poland (23) · Hungary (22)
Russell Esterline (8) · Ron Haberman, MD (5) · Dragos Budinski, Med Dr. (4) · Dragos Budinski, MD (3) · Masayasu Matsumoto, MD, PhD (3) · Evan A Stein, MD PhD (2) · Hyo Soo Kim, M.D., Ph.D (2) · Marc Ditmarsch (2)
PMID 33078867, PMID 27777279, PMID 30183102, PMID 34298554, PMID 21518985, PMID 28964736, PMID 32609313, PMID 35916348, PMID 25614280, PMID 27578134, PMID 28391886, PMID 38063346, PMID 38757725, PMID 41604274, PMID 22087637, PMID 24014831, PMID 25269777, PMID 25431239, PMID 32187462, PMID 37282500, PMID 37565307, PMID 41903707, PMID 12719279, PMID 15311720, PMID 15389231, PMID 16651474, PMID 17325296, PMID 17355745, PMID 17384434, PMID 17533211, PMID 17617940, PMID 17846352, PMID 17985033, PMID 17987126, PMID 18000186, PMID 18196620, PMID 18227370, PMID 18376000, PMID 18376001, PMID 18422390, PMID 18539917, PMID 18676075, PMID 18702965, PMID 18765432, PMID 18940534, PMID 19001024, PMID 19014834, PMID 19059567, PMID 19061694, PMID 19298496
2015 (7), 2005 (5), 2017 (4), 2014 (3), 2016 (2), 2004 (1), 2008 (1), 2023 (1), N01HC95178 (1), N01HC95179 (1), N01HC95180 (1), N01HC95181 (1), N01HC95182 (1), N01HC95183 (1), N01HC95184 (1)